Apply Give

Other ways to search: Events Calendar | UTHSC

RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults

Written by Communications and Marketing

|

RedHill Biopharma Ltd.,  a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill expects to launch Talicia in the U.S. in the first quarter of 2020 with its dedicated sales force.

Top Publishers